198 related articles for article (PubMed ID: 19500496)
1. Review of the SPARCL trial and its subanalyses.
Welch KM
Curr Atheroscler Rep; 2009 Jul; 11(4):315-21. PubMed ID: 19500496
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin: its clinical role in cerebrovascular prevention.
Gaspardone A; Arca M
Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
[TBL] [Abstract][Full Text] [Related]
4. SPARCL: the glimmer of statins for stroke risk reduction.
Armani A; Toth PP
Curr Atheroscler Rep; 2007 Nov; 9(5):347-51. PubMed ID: 18001616
[TBL] [Abstract][Full Text] [Related]
5. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin in stroke: a review of SPARCL and subgroup analysis.
Huisa BN; Stemer AB; Zivin JA
Vasc Health Risk Manag; 2010 Apr; 6():229-36. PubMed ID: 20407630
[TBL] [Abstract][Full Text] [Related]
7. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
Amarenco P; Bogousslavsky J; Callahan AS; Goldstein L; Hennerici M; Sillsen H; Welch MA; Zivin J;
Cerebrovasc Dis; 2003; 16(4):389-95. PubMed ID: 14584489
[TBL] [Abstract][Full Text] [Related]
8. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin in prevention of stroke and transient ischaemic attack.
Amarenco P
Expert Opin Pharmacother; 2007 Nov; 8(16):2789-97. PubMed ID: 17956199
[TBL] [Abstract][Full Text] [Related]
10. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P; Goldstein LB; Sillesen H; Benavente O; Zweifler RM; Callahan A; Hennerici MG; Zivin JA; Welch KM;
Stroke; 2010 Mar; 41(3):426-30. PubMed ID: 20110538
[TBL] [Abstract][Full Text] [Related]
11. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
[TBL] [Abstract][Full Text] [Related]
12. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Chaturvedi S; Zivin J; Breazna A; Amarenco P; Callahan A; Goldstein LB; Hennerici M; Sillesen H; Rudolph A; Welch MA;
Neurology; 2009 Feb; 72(8):688-94. PubMed ID: 18768917
[TBL] [Abstract][Full Text] [Related]
13. Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Fitchett DH; Goodman SG; Langer A
Can J Cardiol; 2008 Sep; 24(9):705-8. PubMed ID: 18787721
[TBL] [Abstract][Full Text] [Related]
14. [Atorvastatin in secondary prevention].
Ongen Z; Yilmaz Y; Karadağ B
Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():23-8. PubMed ID: 19404047
[TBL] [Abstract][Full Text] [Related]
15. High-dose atorvastatin after stroke or transient ischemic attack.
Amarenco P; Bogousslavsky J; Callahan A; Goldstein LB; Hennerici M; Rudolph AE; Sillesen H; Simunovic L; Szarek M; Welch KM; Zivin JA;
N Engl J Med; 2006 Aug; 355(6):549-59. PubMed ID: 16899775
[TBL] [Abstract][Full Text] [Related]
16. High dose atorvastatin after stroke or transient ischaemic attack (SPARCL)--does every stroke patient in Pakistan deserve a statin?
Khan M; Kamran KA
J Pak Med Assoc; 2010 Jun; 60(6):505-6. PubMed ID: 20527658
[No Abstract] [Full Text] [Related]
17. [Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain].
Arrospide A; Mar J; Vivancos-Mora J; Rejas-Gutiérrez J; Caro J
Rev Neurol; 2010 Jul; 51(1):1-11. PubMed ID: 20568062
[TBL] [Abstract][Full Text] [Related]
18. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Goldstein LB; Amarenco P; Lamonte M; Gilbert S; Messig M; Callahan A; Hennerici M; Sillesen H; Welch KM;
Stroke; 2008 Sep; 39(9):2444-8. PubMed ID: 18617654
[TBL] [Abstract][Full Text] [Related]
19. [Important aim of statin therapy: ischemic cardiovascular event (stroke)].
Császár A
Ideggyogy Sz; 2008 Jul; 61(7-8):239-43. PubMed ID: 18763479
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Arca M
Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
